CR20230597A - Inhibidores de alk2 quinasa que contienen imidazol - Google Patents

Inhibidores de alk2 quinasa que contienen imidazol

Info

Publication number
CR20230597A
CR20230597A CR20230597A CR20230597A CR20230597A CR 20230597 A CR20230597 A CR 20230597A CR 20230597 A CR20230597 A CR 20230597A CR 20230597 A CR20230597 A CR 20230597A CR 20230597 A CR20230597 A CR 20230597A
Authority
CR
Costa Rica
Prior art keywords
imidazole
compounds
pharmaceutically acceptable
alk2 kinase
containing inhibitors
Prior art date
Application number
CR20230597A
Other languages
English (en)
Inventor
Yarlagadda S Babu
Wei Lv
Pravin L Kotian
Weihe Zhang
peng-cheng Lu
Andrew E Spaulding
Krishnan Raman
Original Assignee
Biocryst Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocryst Pharm Inc filed Critical Biocryst Pharm Inc
Publication of CR20230597A publication Critical patent/CR20230597A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se divulgan compuestos de la Fórmula I, II, III y IV, y sales aceptables desde el punto de vista farmacéutico de estos. Los compuestos son inhibidores de ALK2 quinasa. Además, se proporcionan composiciones farmacéuticas que comprenden un compuesto de la Fórmula I, II, III o IV, o una sal aceptable desde el punto de vista farmacéutico de este, y métodos que implican el uso de los compuestos o las sales aceptables desde el punto de vista farmacéutico de estos y las composiciones en el tratamiento y la prevención de diversas enfermedades y afecciones, tales como fibrodisplasia osificante progresiva. (I)                          (II)(III)                        (IV) 
CR20230597A 2021-05-25 2022-05-24 Inhibidores de alk2 quinasa que contienen imidazol CR20230597A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163192822P 2021-05-25 2021-05-25
PCT/US2022/030690 WO2022251188A2 (en) 2021-05-25 2022-05-24 Imidazole-containing inhibitors of alk2 kinase

Publications (1)

Publication Number Publication Date
CR20230597A true CR20230597A (es) 2024-02-20

Family

ID=84230377

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230597A CR20230597A (es) 2021-05-25 2022-05-24 Inhibidores de alk2 quinasa que contienen imidazol

Country Status (18)

Country Link
EP (1) EP4346806A2 (es)
JP (1) JP2024520359A (es)
KR (1) KR20240013145A (es)
CN (1) CN117529315A (es)
AR (1) AR125963A1 (es)
AU (1) AU2022283258A1 (es)
BR (1) BR112023024537A2 (es)
CA (1) CA3219966A1 (es)
CL (1) CL2023003503A1 (es)
CO (1) CO2023017975A2 (es)
CR (1) CR20230597A (es)
DO (1) DOP2023000254A (es)
EC (1) ECSP23096182A (es)
IL (1) IL308513A (es)
MX (1) MX2023013742A (es)
TW (1) TW202313625A (es)
UY (1) UY39788A (es)
WO (1) WO2022251188A2 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070244114A1 (en) * 2004-07-06 2007-10-18 Myriad Genetics, Incorporated Compounds and therapeutical use thereof
KR20110071098A (ko) * 2008-09-30 2011-06-28 아스트라제네카 아베 복소환 ｊａｋ 키나제 억제제
AR112027A1 (es) * 2017-06-15 2019-09-11 Biocryst Pharm Inc Inhibidores de alk 2 quinasa que contienen imidazol

Also Published As

Publication number Publication date
CO2023017975A2 (es) 2024-01-15
JP2024520359A (ja) 2024-05-24
CL2023003503A1 (es) 2024-05-03
WO2022251188A8 (en) 2024-01-04
AR125963A1 (es) 2023-08-30
EP4346806A2 (en) 2024-04-10
CN117529315A (zh) 2024-02-06
ECSP23096182A (es) 2024-01-31
WO2022251188A2 (en) 2022-12-01
UY39788A (es) 2023-01-31
WO2022251188A3 (en) 2023-01-05
TW202313625A (zh) 2023-04-01
DOP2023000254A (es) 2023-12-29
AU2022283258A1 (en) 2024-01-04
IL308513A (en) 2024-01-01
KR20240013145A (ko) 2024-01-30
CA3219966A1 (en) 2022-12-01
MX2023013742A (es) 2023-11-28
BR112023024537A2 (pt) 2024-02-06

Similar Documents

Publication Publication Date Title
MX2023004309A (es) Inhibidores de quinasa alk2 que contienen imidazol.
PH12020551717A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
PH12018502227A1 (en) Macrocyclic mcl1 inhibitors for treating cancer
MX2020011294A (es) Derivados de 2-amino-piridina o 2-amino-pirimidina como inhibidores de cinasa dependientes de ciclina.
JOP20220142A1 (ar) مثبطات kras g12c
CR20220062A (es) Inhibidores de shp2 fosfatasa de tipo pirazolo [3,4-b]pirazina
AR067599A1 (es) Derivados de indazol sustituido activos como inhibidores de quinasa
MY189118A (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives
MX352672B (es) Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer.
MX2011009796A (es) Inhibidores de la cinasa pi3.
MX2021011606A (es) Compuestos dirigidos a prmt5.
MX2022008881A (es) Compuesto heterociclico de pirimidin-4(3h)-ona, metodo de preparacion del mismo y su uso farmaceutico.
TN2019000170A1 (en) Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
MX2009009238A (es) Nuevos inhibidores de fosfodiesterasa.
PH12021550825A1 (en) Quinoline derivatives as alpha4beta7 integrin inhibitors
MX2020010942A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
PH12020552244A1 (en) Heterocyclic compounds as trk inhibitors
MX341341B (es) Derivados de benzamida y su uso como inhibidores de proteina de choque termico 90 kda (hsp90).
MX2021012105A (es) Compuestos de pirrol.
SA519410865B1 (ar) مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه
MY195576A (en) Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof
CR20230597A (es) Inhibidores de alk2 quinasa que contienen imidazol
UA98639C2 (en) Phosphodiesterase inhibitors
MX2023005806A (es) Tratamiento de cánceres con mutación en oncogen homologo al virus kirsten de sarcoma de rata (kras).
MX2021014458A (es) Compuestos triciclicos.